
When NICE was first set up in 1999, technology appraisals of new medicines were its sole focus, but over the …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

